Alterity Therapeutics (ATHE) EBIT (2016 - 2019)

Alterity Therapeutics' EBIT history runs 4 years deep, the most recent figure standing at -$3.9 million for Q4 2019.

• In Q4 2019, EBIT fell 0.58% year-over-year to -$3.9 million; the TTM figure through Dec 2019 stood at -$13.2 million (changed N/A YoY), while the FY2025 annual figure was -$7.7 million, up 38.47% from the prior year.
• EBIT was -$3.9 million for Q4 2019 at Alterity Therapeutics, down from -$3.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$2.7 million in Q4 2016 to a low of -$3.9 million in Q4 2019.
• Historically, EBIT has averaged -$3.3 million across 4 years, with a median of -$3.3 million in 2017.
• The sharpest annual moves came in 2018 and 2019: EBIT tumbled 37.71% in 2018, then fell 0.58% in 2019.
• A 4-year view of EBIT shows it stood at -$2.7 million in 2016, then dropped by 1.55% to -$2.8 million in 2017, then plunged by 37.71% to -$3.8 million in 2018, then dropped by 0.58% to -$3.9 million in 2019.
• The last three EBIT figures came in at -$3.9 million (Q4 2019), -$3.8 million (Q4 2018), and -$2.8 million (Q4 2017), per Business Quant data.